Dry age-related macular degeneration progresses slowly but relentlessly, resulting in meaningful loss. Most interventions have focused on watchful waiting rather than proactive support.
Photobiomodulation offers a noninvasive option, targeting retinal bioenergetics and microvascular dynamics. This has led to interest in system-wide adoption, moving beyond single-site pilots.
The question for scientific readers is no longer whether light can modulate retinal physiology but how to implement dosing, measurement, and safety at scale.
The key challenge is to ensure results remain reproducible across operators and clinics.
Author's summary: Scaling photobiomodulation for Dry AMD requires careful implementation.